NEW YORK (Reuters) - Biotech stocks were tracking for their third straight decline on Monday, weighed down by a drop in Gilead Sciences after the latest developments regarding its hepatitis C drug. Shares of the drugmaker were trading down 2.1 percent to $101.45 after Gilead said the next version of the drug, which drew criticism for its previous cost of $84,000, would become more expensive. ...
via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment